Evidence map›Paper›PMID 27209168›Full record

ArticleWorld journal of urology2017

Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy.

Mihai Dorin Vartolomei, Romain Mathieu, Vitaly Margulis, Jose A Karam, Morgan Rouprêt, Ilaria Lucca, Aurélie Mbeutcha, Christian Seitz, Pierre I Karakiewicz, Harun Fajkovic and 10 more

Abstract read
In one paragraph

Article in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mihai Dorin VartolomeiDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Romain MathieuDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Vitaly MargulisDepartment of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Jose A KaramDepartment of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Morgan RouprêtAcademic Department of Urology, La Pitié-Salpetrière Hospital, Assistance Publique-Hôpitaux de Paris, Faculté de Médecine Pierre et Marie Curie, University Paris 6, Paris, France.
Ilaria LuccaDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Aurélie MbeutchaDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Christian SeitzDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada.
Harun FajkovicDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Christopher G WoodDepartment of Urology, MD Anderson Cancer Center, Houston, TX, USA.
Alon Z WeizerDepartment of Urology, University of Michigan Cancer Center, Ann Arbor, MI, USA.
Jay D RamanDivision of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
Nathalie Rioux-LeclercqDepartment of Pathology, Rennes University Hospital, Rennes, France.
Andrea HaitelDepartment of Pathology, Medical University of Vienna, Vienna, Austria.
Karim BensalahDepartment of Urology, Rennes University Hospital, Rennes, France.
Michael RinkDepartment of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alberto BrigantiDepartment of Urology, Vita Salute San Raffaele University, Milan, Italy.
Evanguelos XylinasDepartment of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.
Shahrokh F ShariatDepartment of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSeveral retrospective studies with small cohorts reported neutrophil-to-lymphocyte ratio (NLR) as a prognostic marker in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy (RNU). We aimed at validating the predictive and prognostic role of NLR in a large multi-institutional cohort.

methodsPreoperative NLR was assessed in a multi-institutional cohort of 2477 patients with UTUC treated with RNU. Altered NLR was defined by a ratio >2.7. Logistic regression analyses were performed to assess the association between NLR and lymph node metastasis, muscle-invasive and non-organ-confined disease. The association of altered NLR with recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Cox proportional hazards regression models.

resultsAltered NLR was observed in 1428 (62.8 %) patients and associated with more advanced pathological tumor stage, lymph node metastasis, lymphovascular invasion, tumor necrosis and sessile tumor architecture. In a preoperative model that included age, gender, tumor location and architecture, NLR was an independent predictive factor for the presence of lymph node metastasis, muscle-invasive and non-organ-confined disease (p < 0.001). Within a median follow-up of 40 months (IQR 20-76 months), 548 (24.1 %) patients experienced disease recurrence and 453 patients (19.9 %) died from their cancer. Compared to patients with normal NLR, those with altered NLR had worse RFS (0.003) and CSS (p = 0.002). In multivariable analyses that adjusted for the effects of standard clinicopathologic features, altered NLR did not retain an independent value. In the subgroup of patients treated with lymphadenectomy in addition to RNU, NLR was independently associated with CSS (p = 0.03).

conclusionIn UTUC, preoperative NLR is associated with adverse clinicopathologic features and independently predicts features of biologically and clinically aggressive UTUC such as lymph node metastasis, muscle-invasive or non-organ-confined status. NLR may help better risk stratify patients with regard to lymphadenectomy and conservative therapy.

Indexed as

LymphocytesNephrectomyNeutrophilsAgedCarcinoma, Transitional CellDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateKidney NeoplasmsLeukocyte CountLymphocyte CountMaleMiddle AgedMultivariate AnalysisNeoplasm StagingCarcinomaDeathNeutrophil-to-lymphocyte ratioPrognostic factorRecurrenceUrothelium

Identifiers

PMID27209168
PMCPMC5233730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.